Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.
Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, Sander P, Baptista MJ, Heming JN, Berning P, Wullenkord R, Erdmann T, Lutz M, Veratti P, Ehrenfeld S, Wienand K, Horn H, Goodlad JR, Wilson MR, Anagnostopoulos I, Lamping M, Gonzalez-Barca E, Climent F, Salar A, Castellvi J, Abrisqueta P, Menarguez J, Aldamiz T, Richter J, Klapper W, Tzankov A, Dirnhofer S, Rosenwald A, Mate JL, Tapia G, Lenz P, Miething C, Hartmann W, Chapuy B, Fend F, Ott G, Navarro JT, Grau M, Lenz G. Frontzek F, et al. Nat Commun. 2021 Aug 31;12(1):5183. doi: 10.1038/s41467-021-25405-w. Nat Commun. 2021. PMID: 34465776 Free PMC article.
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumours.
Huettl KS, Staiger AM, Horn H, Frontzek F, Goodlad JR, Tapia G, Rosenwald A, Klapper W, Fend F, Climent F, Castellvi J, Tzankov A, Dirnhofer S, Baptista MJ, Navarro JT, Anagnostopoulos I, Hartmann W, Lenz G, Ott G. Huettl KS, et al. Among authors: frontzek f. Histopathology. 2021 May;78(6):831-837. doi: 10.1111/his.14300. Epub 2020 Dec 25. Histopathology. 2021. PMID: 33165992
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, Truemper L, Held G, Bentz M, Borchmann P, Dreyling M, Viardot A, Kroschinsky FP, Metzner B, Staiger AM, Horn H, Ott G, Rosenwald A, Loeffler M, Lenz G, Schmitz N. Frontzek F, et al. Lancet Haematol. 2021 Apr;8(4):e267-e277. doi: 10.1016/S2352-3026(21)00022-3. Epub 2021 Mar 2. Lancet Haematol. 2021. PMID: 33667420 Clinical Trial.
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Hess G, Hüttmann A, Witzens-Harig M, Dreyling MH, Keller U, Marks R, Ernst T, Pott C, Viardot A, Frontzek F, Trautmann M, Ruckes C, Deuster O, Rosenwald A, Theobald M, Lenz G. Hess G, et al. Among authors: frontzek f. Br J Haematol. 2022 Aug;198(3):482-491. doi: 10.1111/bjh.18161. Epub 2022 Apr 1. Br J Haematol. 2022. PMID: 35362552 Clinical Trial.
Tackling ALK-positive LBCL.
Frontzek F, Lenz G. Frontzek F, et al. Blood. 2022 Oct 20;140(16):1751-1752. doi: 10.1182/blood.2022017742. Blood. 2022. PMID: 36264594 Free article. No abstract available.
Plasmablastic lymphoma: from genetics to treatment.
Frontzek F, Hailfinger S, Lenz G. Frontzek F, et al. Leuk Lymphoma. 2023 Apr;64(4):799-807. doi: 10.1080/10428194.2022.2162341. Epub 2022 Dec 28. Leuk Lymphoma. 2023. PMID: 36577021
Molecular profiling of EBV associated diffuse large B-cell lymphoma.
Frontzek F, Staiger AM, Wullenkord R, Grau M, Zapukhlyak M, Kurz KS, Horn H, Erdmann T, Fend F, Richter J, Klapper W, Lenz P, Hailfinger S, Tasidou A, Trautmann M, Hartmann W, Rosenwald A, Quintanilla-Martinez L, Ott G, Anagnostopoulos I, Lenz G. Frontzek F, et al. Leukemia. 2023 Mar;37(3):670-679. doi: 10.1038/s41375-022-01804-w. Epub 2023 Jan 5. Leukemia. 2023. PMID: 36604606 Free PMC article.
16 results